Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee ReviewSAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update ...

SAN DIEGO, May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offer ...

Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from p ...

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for ...

Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Conference Call February 14, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations James Frakes - Interim Chief Executive Officer and Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Anthony Vendetti - Maxim Group Operator Good day and welcome to the Aethlon Medical Third Quarter Fiscal 2024 Earnings and Corporate Update. [Operator Instructions] Please note, today’s event is ...

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.  Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to_____ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-3632859 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to_____ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-3632859 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to_____ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-3632859 (State or other ju ...

Financial Performance - The company recorded government contract revenue of $574,245 for the fiscal year ended March 31, 2023, compared to $294,165 for the fiscal year ended March 31, 2022, representing an increase of $280,080[301]. - Consolidated operating expenses increased to $12,472,883 for the fiscal year ended March 31, 2023, from $10,715,050 for the fiscal year ended March 31, 2022, an increase of $1,757,833[306]. - The net loss before noncontrolling interests increased to $12,029,786 for the fiscal year ended March 31, 2023, from $10,420,885 for the fiscal year ended March 31, 2022[308]. - The company reported a net cash used in operating activities of approximately $10,505,000 for fiscal 2023, an increase of approximately $738,000 compared to $9,767,000 in fiscal 2022[326]. - The company raised approximately $8,915,000 from financing activities in fiscal 2023, a decrease from $17,368,000 in fiscal 2022[327]. Cash and Capital Management - As of March 31, 2023, the company had a cash balance of $14,532,943 and working capital of $13,585,477, compared to $17,072,419 and $16,332,958, respectively, at March 31, 2022[309]. - The company anticipates continued negative cash flows and net losses for the foreseeable future, necessitating additional capital raises through equity and/or debt financing[320]. - The company expects future capital requirements to depend on various factors, including progress with clinical trials and regulatory approvals[320]. - The company has no obligation to sell any shares under the 2022 ATM Agreement, and sales can be suspended or terminated at any time[317]. - In the fiscal year ended March 31, 2023, the company raised net proceeds of $8,927,211 from the sale of 7,480,836 shares at an average price of $1.19 per share under the 2022 ATM Agreement[313]. - The company raised net proceeds of $1,086,119 from the sale of 1,778,901 shares at an average price of $0.61 per share under the 2022 ATM Agreement[340]. - The company raised approximately $11,659,044 from the sale of 1,380,555 shares at a purchase price of $9.00 per share in a registered direct financing during fiscal 2022[318]. Clinical Trials and Research - The company entered into an agreement with NAMSA to oversee clinical trials for the Hemopurifier in oncology indications, with initial trials anticipated to begin in Australia[289]. - The FDA approved a supplement to the company's open IDE for the Hemopurifier to test it in patients with COVID-19, with a study designed to enroll up to 40 subjects[292]. - The company launched a wholly owned subsidiary in Australia to conduct clinical research and seek regulatory approval for the Hemopurifier[293]. - The company is investigating the use of the Hemopurifier in organ transplant settings to potentially reduce complications following transplantation[295]. - Clinical trial expenses for the preparation of the planned oncology trial in Australia were $103,602 in fiscal 2023, with expectations for continued increases in these expenses[319]. - The company terminated its subaward arrangement with the University of Pittsburgh due to inability to recruit patients for the clinical trial[305]. Operational Challenges - The company is monitoring the impact of inflation, recent bank failures, and the war in Ukraine on its business and capital access[299]. - Rent expense increased by $117,772 in fiscal 2023, with expectations for further increases in the foreseeable future[319]. Director Compensation - In April 2023, three non-employee directors were granted 116,279 RSUs each, priced at $0.43 per share, under the Director Compensation Policy[341]. - The RSUs granted to directors are subject to vesting in four equal installments, with 25% vesting on June 30, September 30, December 31, 2023, and March 31, 2024[341].